Biological Rhythms In COVID-19 Vaccine Effectiveness
Hazan, G.; Duek, O.; Alapi, H.; Mok, H.; Ganniger, A.; Ostendorf, E.; Gierasch, C.; Chodick, G.; Greenberg, D.; Haspel, J. A.
Show abstract
ImportanceCircadian rhythms affect fundamental immune processes, but how this translates to clinical outcomes like real-world vaccine effectiveness is unclear. ObjectiveTo examine associations between Coronavirus Infectious Disease 2019 (COVID-19) vaccination timing and effectiveness. Design, Setting, and ParticipantsRetrospective cohort study of database records from Maccabi Healthcare Services (MHS), a major Israeli Health Maintenance Organization (HMO). We included all individuals over 12 with at least one timestamped vaccine dose and no documented COVID-19 infection prior to completing the initial 2-dose immunization series (n=1,515,754, 99.2% receiving BNT162b2). Database records spanned December 19, 2020, to April 25, 2022, encompassing two spikes in COVID infection dominated by the delta (B.1.617.2) and omicron (B.1.1.529) SARS-CoV-2 variants. Main Outcomes and MeasuresOutcomes included COVID-19 breakthrough infection and COVID-19 associated emergency department (ED) visits. Our main comparison was between patients vaccinated exclusively during morning hours (8:00-11:59), afternoon (12:00-15:59), or evening hours (16:00-19:59). We employed Cox multivariate regression to adjust for differences in age, sex, and co-morbidities. ResultsBreakthrough infections differed based on vaccination time, with lowest rates associated with late morning to early afternoon, and highest rates with evening vaccination. Vaccination timing remained significant after adjustment for patient age, sex, and co-morbidities (HR=0.88 afternoon vs. evening, [95% CI 0.87-0.90]). Results were consistent in patients who received the basic two-dose vaccine series and who received booster doses. The relationship between COVID-19 immunization time and breakthrough infection risk was sinusoidal, consistent with a biological rhythm in vaccine effectiveness. Vaccination timing altered breakthrough infection risk by 8.6-25% in our cohort, depending on patient age and dose number. The benefits of daytime vaccination were concentrated in younger and elderly patients. In contrast to breakthrough infections, COVID-19 related ED visits correlated with age and medical comorbidities but not with time of vaccination. Conclusions and RelevanceWe report a significant association between the time of COVID-19 vaccination and its clinical effectiveness in terms of breakthrough infection. These data have implications for mass vaccination programs. KEY POINTS QuestionDoes the time of day patients receive their COVID-19 vaccinations influence their clinical benefit? FindingsIn this population-level cohort study that included 1,515,754 individuals aged 12 and over, COVID-19 vaccination during the late morning to early afternoon was associated with fewer breakthrough infections compared to other times. Vaccination timing altered breakthrough infection risk by 8.6-25%, depending on patient age and dose number. MeaningPrioritizing children and the elderly for late morning to early afternoon immunization could improve the effectiveness of mass vaccinations against COVID-19, and potentially other infectious diseases.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 95%
- Distinct COVID-19 vaccine combinations result in divergent immune responses 95%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 94%
Similar papers in this journal
- Antibody therapy reverses biological signatures of COVID-19 progression 93%
- GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR) 93%
- Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study 93%
Similar papers in this journal
- FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system 94%
- Real-time analysis of a mass vaccination effort via an Artificial Intelligence platform confirms the safety of FDA-authorized COVID-19 vaccines 94%
- Superior antibody immunogenicity of a RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.